Pomerantz LLP is investigating Omeros Corporation for potential securities fraud following a significant stock price drop. The decline occurred after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion on Omeros's drug narsoplimab for treating TA-TMA. This negative opinion caused Omeros's stock to fall nearly 20% on June 26, 2026. The investigation will determine if Omeros or its executives engaged in unlawful business practices related to this event.
Rogers Communication reported better-than-expected Q2 2026 results, with earnings per share of $0.83 beating estimates of $0.80 and revenue reaching $3.96 billion, surpassing forecasts. The company showed improved financial discipline by increasing f...
The global Botulinum Toxin in Urology Market is projected to grow from approximately USD 1.16 billion in 2026 to USD 1.98 billion by 2035, at a CAGR of 6.08%. Growth is fueled by increasing prevalence of urological disorders like overactive bladder, ...
BioLife Solutions stock was downgraded to a 'Hold' rating with a $31 price target by Lake Street amid its proposed $1.5 billion acquisition by Repligen Corporation. The deal, a cash-and-stock offer, is under legal scrutiny by Halper Sadeh LLC, which ...
Altius Minerals Corporation sees a price target increase from C$51 to C$54 by Bank of Montreal, reflecting optimism despite a 'Market Perform' rating. The company projects record Q2 2026 royalty revenue of about $30 million, up from $12.7 million a y...
Badger Meter reported Q2 2026 earnings per share of $1.02 and revenue of $222.32 million, both slightly above analyst expectations. Although revenue declined 7% year-over-year, the company saw a 9% sequential increase in base sales due to new advance...
